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OBJECTIVES: The EQ-5D is the most used questionnaire to obtain utilities. Because
of its index ceiling effect, Tobit and CLAD-CQR (Censored Least Absolute Deviations
– Censored Quantile Regression) models are often used instead of Ordinal Least
Squares for its modelization. CLAD models are usually presented as a robust alter-
native to the Tobit misspecification problems in presence of heteroskedasticity.
The aim of this study is to evaluate the suitability of the CLAD-CQR models for the
estimation of utilities and QALYs (Quality-Adjusted Life Years), to evaluate the
impact of different chronic conditions in Catalan population’s health. METHODS:
The EQ-5D was interview-administered in the 2006 Catalan Health Interview Sur-
vey, a cross-sectional study of a representative sample of the non-institutionalised
general population (n15,926). As well as CLAD-CQR, Tobit model was adjusted to
assess utility losses associated with 15 chronic conditions. Goodness of fit was
assessed by cross-validation (Mean Square Error –MSE-, Mean Absolute Deviations
–MAD-). RESULTS: As ceiling effect was over 50%, CQR models on the 30 percentile
had to be applied instead of CLAD models on the median. CQR showed a slightly
worse fit to data (MSE0.084, MAD0.246) than Tobit (MSE0.068, MAD0.218).
The impact of the different chronic conditions measured in QALYs obtained from
the CQR was on average around 70% larger than the ones of the Tobit model.
CONCLUSIONS: Tobit and CLAD-CQR model latent quality of life, not anchored in
0death and 1perfect health. While Tobit allows an estimation of observed util-
ities and marginal effects, interpretable as QALYs, CQR do not in the case of right-
censoring. This leads to overestimation of effects and makes CLAD-CQR models
inappropriate for obtaining QALYs, just as the untransformed Tobit’s latent vari-
able. Moreover, the suitability of modelling percentiles differing from the median
should be discussed.
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OBJECTIVES: Regulators of medical technologies are facing increasing pressure to
make their deliberations concerning the benefits and risk more transparent. Both
benefits and risks are often measured via multiple competing outcomes. Hence,
MCDA models like the Analytic Hierarchy/Network Process are valuable tools in
quantifying decision trade-offs. The objective of this paper is to demonstrate the
use of MCDA models for benefit-risk assessment and the use of sensitivity analysis
to assess the impact of uncertainty and patient heterogeneity.METHODS:Using an
existing data set about anti-depressants we construct a decision model for use with
AHP weights, including clinical endpoints, adverse events and quality of life. AHP
priorities for the main criteria (benefits and risks) were obtained from the general
public (n15) using face–to-face interview. After base-case analysis of decision
trade-offs, three forms of sensitivity analysis for MCDA models were employed.
RESULTS: We applied three forms of sensitivity analysis, including 1) manual ad-
justment of criteria weights using a slider; 2) probabilistic sensitivity analysis (PSA)
of the criteria weights; and 3) PSA of the expected drug performance on each of the
criteria. Examples will be graphically presented and discussed. CONCLUSIONS:
One of the advantages of AHP/ANP is its ease of use. However, in order to make
judgments about benefits and risks decision makers, may wish to generalize to a
wider population and as well as to quantify decision trade-offs in subgroups of
patients. The methods employed provide this flexibility. However, the strategy
chosen should not be more complex than necessary to support the decision maker.
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OBJECTIVES: It is becoming increasingly common that early stage drug candidates
have potential applications in several therapy areas. This is especially prevalent
where several diseases share a similar aetiology. Areas such as immunology, on-
cology and metabolic disorders can have ailments that are characterised by differ-
ent physiological involvement but share a similar underlying cause. The objective
of this study was to model the impact of a multiple indication launch on drug
revenue over time, as well as develop a tool to enable launch strategy scenario
testing. METHODS: The attractiveness and potential NPV of each therapy area is
assessed using a combination of qualitative and quantitative methods. Therapy
areas are scored and ranked by defined metrics allowing the optimum therapy area
to be selected as the first launch indication. The assessment is repeated for the
remaining therapy areas to account for changes in pricing dynamics from the
initial launch indication, to generate the next most attractive therapy area and so
on. NPV for the drug is then calculated based on a trade-off between patient pop-
ulation size and pricing dynamics across indications. RESULTS: In general, the
larger patient populations translate into lower drug costs to meet with budget
impact thresholds. It is therefore vital for manufacturers to understand the optimal
trade-off between price and population size across indications in order to maxi-
mise the overall commercial potential of a drug. When different indications have
significantly differently sized patient populations, drug pricing becomes an issue.
The research concluded that if the correct strategy is employed, a drug launch
strategy can be optimised to generate the maximum possible revenue over the
greatest number of indications. CONCLUSIONS: Modeling changes in price and
population size during multiple-indication launches can be a vital tool in under-
standing total revenue potential of a new product, and optimal launch sequencing.
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OBJECTIVES:To compare three methods of measuring multimorbidity according to
the use of health resources (cost of care) in primary health care (PHC). METHODS:
Design: retrospective study using computerized medical records. Setting: thirteen
PHC teams in Catalonia (Spain). Participants: assigned patients requiring care in
2009. Main measurements: the socio-demographic variables, co-morbidity and
costs. Methods of comparison were: a) Combined Comorbidity Index (CCI): an index
itself was developed from the scores of acute and chronic episodes; b) Charlson
Index (ChI); and c) Adjusted Clinical Groups case-mix: resource use bands (RUB).
The cost model was constructed by differentiating between fixed (operational) and
variable costs. Statistical analysis: was developed 3 multiple lineal regression mod-
els to assess the explanatory power of each measure of co-morbidity were com-
pared from the of determination coefficient (R2), p0.05. RESULTS: A total fo
227,235 patients were included. Woman: 55.6%, average age was 44.1 years, mean
episodes/year: 4.5; average visits/patient/year: 8.1, the mean unit of cost was
€654.2. The CCI explained a R250.4%, the ChI a R229.2% and RUB a R239.7% of
the variability of the cost. The ICC is acceptable behaviour, albeit with low scores (1
to 3 points), showed no conclusive results. CONCLUSIONS: The CCI may be a sim-
ple method of predicting PHC costs in routine clinical practice. If confirmed, these
results will allow improvements in the comparison of the case-mix.
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OBJECTIVES: When evaluating healthcare interventions, decision-makers are in-
creasingly asked to consider multiple criteria to support their decision. The MCDA-
based EVIDEM framework was developed to support this process. It includes a
simple weight elicitation technique, designed to be easily applicable by a broad
range of users. The objective of this study was to compare the EVIDEM technique
with more traditional techniques. METHODS: An online questionnaire was devel-
oped comparing the EVIDEM technique with four alternative techniques including
AHP, best/worst scaling, ranking and point-allocation. A convenience sample of 60
Dutch and Canadian students were asked to fill out the questionnaires as if they
were sitting in an advisory committee for reimbursement/prioritization of health-
care interventions. They were asked to provide weights for 14 criteria using two
techniques, and to provide feedback on ease of use and clarity of concepts of the
different techniques. RESULTS: Results based on the first 30 responses show that
EVIDEM is easy to understand and takes little time to complete, three minutes on
average. Criteria weights derived using the EVIDEM technique and best/worst scal-
ing are divergent. Comparing the rank order of criteria respondents gave using
these two techniques; there is more resemblance in rank order of criteria weighted
with the EVIDEM technique. Compared to AHP/ranking/point-allocation, EVIDEM
takes less time to complete but is only preferred by 33% of decision-makers. AHP/
ranking and point allocation were often described as clearer and more reflective of
the respondents’ opinion. CONCLUSIONS: The simple technique is proposed as a
starting point for users wishing to adapt the EVIDEM framework to their own con-
text. Other techniques may be preferred and their impact on the MCDA value
estimate generated by applying the framework is being explored. This project is
part of a large collaborative work that includes developing and validating this
framework to facilitate sound and efficient MCDA-applications.
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OBJECTIVES: Personalized medicine (PM) takes into account that diagnostic and
therapeutic health technologies should be based on individual characteristics of
patients such as risk profile and treatment response. Health policy decisions under
constrained resources in PM require adequate evaluation methods that incorpo-
rate economic aspects and multiple characteristics (e.g., genotypes, blood mark-
ers). Microsimulation is a technique to evaluate health technologies, policies and
interventions based on individual characteristics. Our goal was to identify and
contrast different microsimulation approaches and discuss the applicability of
these approaches in the evaluation of PM. METHODS: We performed a review on
microsimulation and applications in social sciences, health care and politics. As-
sessment criteria include the modeling of patient characteristics/patient history/
prior events, the way events or transitions between health states are modeled, the
inclusion of life years/utilities/costs, open/closed cohort approach, and the way
time is modeled.RESULTS: Identified approaches range from state-transition mod-
A424 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
